✦ LIBER ✦

PR95 DISEASE FREE PERIOD AND SURVIVAL AFTER INITIAL TREATMENT OF HER2 NEGATIVE LOCALLY ADVANCED BREAST CANCER

✍ Scribed by Han, Sehwan; Park, In Suk; Kim, Jung Bin

Book ID: 122156281
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 51 KB
Volume: 22
Category: Article
ISSN: 0960-9776
DOI: 10.1016/S0960-9776(13)70108-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Tailored preoperative treatment of local

Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel

✍ Rosalba Torrisi; Alessandra Balduzzi; Raffaella Ghisini; Andrea Rocca; Luca Bott 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 292 KB

Pathologic stage is most prognostic of d

Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation

✍ Hak-Mien Quah; Joanne F. Chou; Mithat Gonen; Jinru Shia; Deborah Schrag; Leonard 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 181 KB

## Abstract ## BACKGROUND. Preoperative chemoradiation is the standard treatment for locally advanced rectal cancer. However, it is uncertain whether pretreatment clinical stage, degree of response to neoadjuvant treatment, or pathologic stage is the most reliable predictor of outcome. This study

Analysis of biomarkers (P PTEN, and IGF-

Analysis of biomarkers (P PTEN, and IGF-IR) after preoperative systemic treatment with the combination of docetaxel and trastuzumab in patients with locally advanced HER2-overexpressing breast cancer (Tokai Breast Cancer Clinical Research Group: TBCRG)

✍ H. Iwata; M. Sawaki; Y. Sato; M. Wada; T. Toyama; E. Sasaki; Y. Yatabe; T. Imai 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 67 KB

5026 POSTER DISCUSSION Sorafenib (SOR) P

5026 POSTER DISCUSSION Sorafenib (SOR) Plus Chemotherapy (CRx) for Treatment (tx) of Patients (pts) With HER2-negative Locally Advanced (adv) or Metastatic (met) Breast Cancer (BC) and Prior Bevacizumab (BEV): Subgroup Analysis of AC01B07

✍ Hudis, C.A.; Hermann, R.C.; Makari-Judson, G.; Isaacs, C.; Beck, J.T.; Kaklamani 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 43 KB

The combination of FDG PET and dynamic c

The combination of FDG PET and dynamic contrast-enhanced MRI improves the prediction of disease-free survival in patients with advanced breast cancer after the first cycle of neoadjuvant chemotherapy

✍ Lim, Ilhan; Noh, Woo Chul; Park, Jihyun; Park, Ji Ae; Kim, Hyun-Ah; Kim, Eun-Kyu 📂 Article 📅 2014 🏛 Springer 🌐 English ⚖ 800 KB